Get the Stockscreener App
173.79
0.73%
-1.28
After Hours:
172.98
-0.81
-0.47%
Belite Bio Inc Adr stock is traded at $173.79, with a volume of 143.73K.
It is down -0.73% in the last 24 hours and down -2.13% over the past month.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
See More
Previous Close:
$175.07
Open:
$179.99
24h Volume:
143.73K
Relative Volume:
0.72
Market Cap:
$7.00B
Revenue:
-
Net Income/Loss:
$-77.61M
P/E Ratio:
-75.63
EPS:
-2.2979
Net Cash Flow:
-
1W Performance:
-10.24%
1M Performance:
-2.13%
6M Performance:
+0.02%
1Y Performance:
+153.52%
1-Day Range:
$171.21
$179.99
1-Week Range:
$171.21
$198.58
52-Week Range:
$64.80
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
173.79 | 7.00B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio at Cantor healthcare conference: tinlarebant advances By Investing.com - Investing.com India
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs By Investing.com - Investing.com South Africa
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs - Investing.com
Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares - Investing.com
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com Nigeria
Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Mizuho raises Belite Bio stock price target on Japan drug filing By Investing.com - Investing.com South Africa
Belite Bio at Wells Fargo conference: nda review lifts stakes By Investing.com - Investing.com Canada
Belite Bio files Japan NDA for Stargardt disease drug - grafa.com
Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com Nigeria
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease - TipRanks
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt... - markets.businessinsider.com
Belite Bio (NASDAQ: BLTE) seeks Japan OK for Stargardt pill that could be a first - Stock Titan
Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com South Africa
Belite Bio Pops As Wall Street Backs Stargardt Bet - TipRanks
Canaccord initiates Belite Bio stock with buy on Stargardt therapy - Investing.com
Belite Bio Surges As Tinlarebant Nears FDA Decision - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans - Investing.com
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - Yahoo Finance
Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Barchart.com
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Trading Systems Reacting to (BLTE) Volatility - Stock Traders Daily
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - The Manila Times
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Canada
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada
Belite Bio Q2 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com Canada
Belite Bio Q2 Earnings Call Highlights - Yahoo Finance
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):